Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT^® studies

References

• BuistASMcBurnieMAVollmerWMGillespieSBurneyPManninoDMInternational variation in the prevalence of COPD (the BOLD Study): a population-based prevalence studyLancet200737074175017765523
   PubMed Web of Science ®Google Scholar
• HalbertRJNatoliJLGanoABadamgaravEBuistASManninoDMGlobal burden of COPD: systematic review and meta-analysisEur Respir J20062852353216611654
   PubMed Web of Science ®Google Scholar
• PenaVSMiravitllesMGabrielRJimenez-RuizCAVillasanteCMasaJFGeographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological studyChest200011898198911035667
   PubMed Web of Science ®Google Scholar
• LopezADShibuyaKRaoCMathersCDHansellALHeldLSChronic obstructive pulmonary disease: current burden and future projectionsEur Respir J20062739741216452599
   PubMed Web of Science ®Google Scholar
• CelliBRMacNeeWcommittee membersStandards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J20042393294615219010
   PubMed Web of Science ®Google Scholar
• JemalAWardEHaoYThunMTrends in the leading causes of death in the United States, 1970–2002JAMA20052941255125916160134
   PubMed Web of Science ®Google Scholar
• World Health Organization Chronic obstructive pulmonary disease (COPD) fact sheet No. 315;2008.
   Google Scholar
• MiravitllesMMurioCGuerreroTGisbertRCosts of chronic bronchitis and COPD: a 1-year follow-up studyChest200312378479112628879
   PubMed Web of Science ®Google Scholar
• Serra-BatllesJPlazaVMorejonEComellaABruguesJCosts of asthma according to the degree of severityEur Respir J199812132213269877485
   PubMed Web of Science ®Google Scholar
• PauwelsRARabeKFBurden and clinical features of chronic obstructive pulmonary disease (COPD)Lancet200436461362015313363
   PubMed Web of Science ®Google Scholar
• CooperCBThe connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and functionAm J Med2006119213116996896
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2008 Update. www.goldcopd.org. 2–11–2008
   Google Scholar
• TraverGAClineMGBurrowsBPredictors of mortality in chronic obstructive pulmonary disease. A 15-year follow-up studyAm Rev Respir Dis1979119895902453709
   PubMed Web of Science ®Google Scholar
• SchunemannHJDornJGrantBJWinkelsteinWJrTrevisanMPulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health StudyChest200011865666410988186
   PubMed Web of Science ®Google Scholar
• YoungRPHopkinsREatonTEForced expiratory volume in one second: not just a lung function test but a marker of premature death from all causesEur Respir J20073061662217906084
   PubMed Web of Science ®Google Scholar
• ManninoDMDavisKJLung function decline and outcomes in an elderly populationThorax20066147247716517577
   PubMed Web of Science ®Google Scholar
• FletcherCPetoRThe natural history of chronic airflow obstructionBMJ1977116451648871704
   PubMed Web of Science ®Google Scholar
• AnthonisenNRConnettJEKileyJPAltoseMDBaileyWCBuistASEffects of smoking intervention and the use of an inhaled anti-cholinergic bronchodilator on the rate of decline of FEV1. The Lung Health StudyJAMA1994272149715057966841
   PubMed Web of Science ®Google Scholar
• BurchfielCMMarcusEBCurbJDMacLeanCJVollmerWMJohnsonLREffects of smoking and smoking cessation on longitudinal decline in pulmonary functionAm J Respir Crit Care Med1995151177817857767520
   PubMed Web of Science ®Google Scholar
• ScanlonPDConnettJEWallerLAAltoseMDBaileyWCBuistASSmoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health StudyAm J Respir Crit Care Med200016138139010673175
   PubMed Web of Science ®Google Scholar
• AnthonisenNRConnettJEMurrayRPSmoking and lung function of Lung Health Study participants after 11 yearsAm J Respir Crit Care Med200216667567912204864
   PubMed Web of Science ®Google Scholar
• CazzolaMMacNeeWMartinezFJRabeKFFranciosiLGBarnesPJOutcomes for COPD pharmacological trials: from lung function to biomarkersEur Respir J20083141646918238951
   PubMed Web of Science ®Google Scholar
• CelliBRCoteCGLareauSCMeekPMPredictors of Survival in COPD: more than just the FEV1Respir Med2008102Suppl 1S27S3518582794
   PubMed Web of Science ®Google Scholar
• CooperCBDransfieldMPrimary care of the patient with chronic obstructive pulmonary disease-part 4: understanding the clinical manifestations of a progressive diseaseAm J Med2008121S33S4518558106
   PubMed Web of Science ®Google Scholar
• KerstjensHARijckenBSchoutenJPPostmaDSDecline of FEV1 by age and smoking status: facts, figures, and fallaciesThorax1997528208279371217
   PubMed Web of Science ®Google Scholar
• DonaldsonGCSeemungalTARBhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax20025784785212324669
   PubMed Web of Science ®Google Scholar
• DecramerMRutten-van MolkenMDekhuijzenPNTroostersTvan HerwaardenCPellegrinoREffects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trialLancet20053651552156015866309
   PubMed Web of Science ®Google Scholar
• PauwelsRALofdahlCGLaitinenLASchoutenJPPostmaDSPrideNBLong-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smokingN Engl J Med19993401948195310379018
   PubMed Web of Science ®Google Scholar
• VestboJSorensenTLangePBrixATorrePViskumKLong-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trialLancet19993531819182310359405
   PubMed Web of Science ®Google Scholar
• The Lung Health Study Research GroupEffect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary diseaseN Engl J Med20003431902190911136260
   PubMed Web of Science ®Google Scholar
• BurgePSCalverleyPMAJonesPWSpencerSAndersonJAMaslenTKRandomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trialBMJ20003201297130310807619
   PubMed Web of Science ®Google Scholar
• SutherlandERAllmersHAyasNTVennAJMartinRJInhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysisThorax20035893794114586043
   PubMed Web of Science ®Google Scholar
• HighlandKBStrangeCHeffnerJELong-term effects of inhaled in patients with chronic obstructive pulmonary corticosteroids on FEV1 disease. A meta-analysisAnn Intern Med200313896997312809453
   PubMed Web of Science ®Google Scholar
• SorianoJBSinDDZhangXCampPGAndersonJAAnthonisenNRA pooled analysis of FEV 1 decline in COPD patients randomized to inhaled corticosteroids or placeboChest200713168268917356080
   PubMed Web of Science ®Google Scholar
• Garcia-AymerichJLangePBenetMSchnohrPAntoJMRegular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort studyAm J Respir Crit Care Med200717545846317158282
   PubMed Web of Science ®Google Scholar
• AnzuetoATashkinDMenjogeSKestenSOne-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropiumPulm Pharmacol Ther200518758115649848
   PubMed Web of Science ®Google Scholar
• SorianoJBVestboJPrideNBKiriVMadenCMaierWCSurvival in COPD patients after regular use of fluticasone propionate and salmeterol in general practiceEur Respir J20022081982512412670
   PubMed Web of Science ®Google Scholar
• SinDDWuLAndersonJAAnthonisenNRBuistASBurgePSInhaled corticosteroids and mortality in chronic obstructive pulmonary diseaseThorax20056099299716227327
   PubMed Web of Science ®Google Scholar
• VestboJThe TORCH (towards a revolution in COPD health) survival study protocolEur Respir J20042420621015332386
   PubMed Web of Science ®Google Scholar
• CelliBRThomasNEAndersonJAFergusonGTJenkinsCRJonesPWEffect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH studyAm J Respir Crit Care Med200817833233818511702
   PubMed Web of Science ®Google Scholar
• DecramerMCelliBTashkinDPPauwelsRABurkhartDCassinoCClinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trialCOPD2004130331217136995
   PubMedGoogle Scholar
• CalverleyPMAAndersonJACelliBFergusonGTJenkinsCJonesPWSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med200735677578917314337
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSBurkhartDKestenSMenjogeSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med20083591543155418836213
   PubMed Web of Science ®Google Scholar
• RabeKFHurdSAnzuetoABarnesPJBuistSACalverleyPGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med200717653255517507545
   PubMed Web of Science ®Google Scholar
• AnthonisenNRBronchodilator response in chronic obstructive pulmonary diseaseAm Rev Respir Dis19861338148193706890
   PubMed Web of Science ®Google Scholar
• DorinskyPMReisnerCFergusonGTMenjogeSSSerbyCWWitekTJJrThe combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPDChest199911596697110208193
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBDecramerMLiuDBurkhartDCassinoCBronchodilator responsiveness in patients with COPDEur Respir J20083174275018256071
   PubMed Web of Science ®Google Scholar
• BleeckerEREmmettACraterGKnobilKKalbergCLung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibilityPulm Pharmacol Ther20082168268818541448
   PubMed Web of Science ®Google Scholar
• SuissaSMedications to modify lung function decline in chronic obstructive pulmonary disease: some hopeful signsAm J Respir Crit Care Med200817832232318676961
   PubMed Web of Science ®Google Scholar
• BoltonCEIonescuAAShielsKMPettitRJEdwardsPHStoneMDAssociated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med20041701286129315374843
   PubMed Web of Science ®Google Scholar
• ScholsAMWJSlangenJVolovicsLWoutersEFMWeight loss is a reversible factor in the prognosis of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med1998157179117979620907
   PubMed Web of Science ®Google Scholar
• AnzuetoAMiravitllesMModifying the clinical course of COPDHot Topics in Respiratory Medicine20087719
   Google Scholar
• CrooksSWBayleyDLHillSLStockleyRABronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4Eur Respir J20001527428010706491
   PubMed Web of Science ®Google Scholar
• StanescuDSannaAVeriterCKostianevSCalcagniPGFabbriLMAirways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophilsThorax1996512672718779129
   PubMed Web of Science ®Google Scholar
• GompertzSBayleyDLHillSLStockleyRARelationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPDThorax200156364111120902
   PubMed Web of Science ®Google Scholar
• SeemungalTARDonaldsonGCPaulEABestallJCJeffriesDJWedzichaJAEffect of exacerbation on quality of life in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med1998157141814229603117
   PubMed Web of Science ®Google Scholar
• MiravitllesMFerrerMPontAZalacainRAlvarez-SalaJLMasaFEffect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up studyThorax20045938739515115864
   PubMed Web of Science ®Google Scholar
• DollHMiravitllesMHealth-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literaturePharmacoeconomics20052334536315853435
   PubMed Web of Science ®Google Scholar
• Soler-CataluñaJJMartínez-GarcíaMÁRománSánchez PSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax20056092593116055622
   PubMed Web of Science ®Google Scholar
• MiravitllesMMurioCGuerreroTGisbertRPharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPDChest20021211449145512006427
   PubMed Web of Science ®Google Scholar
• AaronSDFergussonDMarksGBSuissaSVandemheenKLDoucetteSCounting, analysing and reporting exacerbations of COPD in randomised controlled trialsThorax20086312212817702790
   PubMed Web of Science ®Google Scholar
• VinckenWvan NoordJAGreefhorstAPMBantjeThAKestenSKorduckiLImproved health outcomes in patients with COPD during 1 yr’s treatment with tiotropiumEur Respir J20021920921611871363
   PubMed Web of Science ®Google Scholar
• BrusascoVHodderRMiravitllesMKorduckiLTowseLKestenSHealth outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPDThorax20035839940412728159
   PubMed Web of Science ®Google Scholar
• BarrRGBourbeauJCamargoCARamFSInhaled tiotropium for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev2005CD00287615846642
   PubMed Web of Science ®Google Scholar
• DusserDBravoMLIaconoPThe effect of tiotropium on exacerbations and airflow in patients with COPDEur Respir J20062754755516507855
   PubMed Web of Science ®Google Scholar
• PowrieDJWilkinsonTMDonaldsonGCJonesPScrineKVielKEffect of tiotropium on sputum and serum inflammatory markers and exacerbations in chronic obstructive pulmonary diseaseEur Respir J20073047247817504798
   PubMed Web of Science ®Google Scholar
• NiewoehnerDERiceKCoteCPaulsonDCooperJAJrKorduckiLPrevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trialAnn Intern Med200514331732616144890
   PubMed Web of Science ®Google Scholar
• CalverleyPPauwelsRVestboJJonesPPrideNGulsvikACombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialLancet200336144945612583942
   PubMed Web of Science ®Google Scholar
• CasanovaCCoteCde TorresJPAguirre-JaimeAMarinJMPinto-PlataVThe Inspiratory to total lung capacity ratio predicts mortality in patients with COPDAm J Respir Crit Care Med200517159159715591470
   PubMed Web of Science ®Google Scholar
• CelliBZuWallackRWangSKestenSImprovement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumesChest20031241743174814605043
   PubMed Web of Science ®Google Scholar
• O’DonnellDEFlügeTGerkenFHamiltonAWebbKAguilaniuBEffects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in patients with COPDEur Respir J20042383284015218994
   PubMed Web of Science ®Google Scholar
• CasaburiRKukafkaDCooperCBWitekTJJrKestenSImprovement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPDChest200512780981715764761
   PubMed Web of Science ®Google Scholar
• MaltaisFHamiltonAMarciniukDHernandezPSciurbaFCRichterKImprovements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPDChest20051281168117816162703
   PubMed Web of Science ®Google Scholar
• O’DonnellDESciurbaFCelliBMahlerDAWebbKAKalbergCJEffect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPDChest200613064765616963658
   PubMed Web of Science ®Google Scholar
• CasaburiRMahlerDAJonesPWWannerASan PedroGZuWallackRLA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J20021921722411866001
   PubMed Web of Science ®Google Scholar
• SpencerSCalverleyPMABurgePSJonesPWHealth status deterioration in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200116312212811208636
   PubMed Web of Science ®Google Scholar
• SinghSLokeYKFurbergCDInhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysisJAMA20083001439145018812535
   PubMed Web of Science ®Google Scholar
• La VecchiaCFabbriLMPrevention of death in COPDN Engl J Med20073562211221217526088
   PubMed Web of Science ®Google Scholar
• CalverleyPMInhaled corticosteroids are beneficial in chronic obstructive diseaseAm J Respir Crit Care Med200016134134210673165
   PubMed Web of Science ®Google Scholar
• BarnesPJInhaled corticosteroids are not beneficial in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200016134234410673166
   PubMed Web of Science ®Google Scholar
• KestenSJaraMWentworthCLanesSPooled clinical trial analysis of tiotropium safetyChest20061301695170317166984
   PubMed Web of Science ®Google Scholar
• ErnstPGonzalezAVBrassardPSuissaSInhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumoniaAm J Respir Crit Care Med200717616216617400730
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAHaganGAnsariZStockleyRAThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med2008177192617916806
   PubMed Web of Science ®Google Scholar
• QuanjerPHStandardised lung function testing of the European Community for Coal and SteelBull Eur Physiopathol Respir1983197106850151
   PubMedGoogle Scholar